A personalized daily biotech newsletter, written just for you

Biotech may be the hardest sector to follow well. The science is deep, the regulatory process is opaque, clinical trial readouts require interpretation, and industry coverage swings between press-release stenography and paywalled specialist analysis. Whether you follow it as an investor, a scientist, or a fascinated outsider, the gap between headline and understanding is wide.

Briefed closes it one reader at a time. You describe your angle - 'gene editing and cell therapy, with context on how trials and approvals actually work', or 'the business side: biotech funding, M&A, and platform companies', or 'oncology research for a scientifically literate lay reader' - and Claude writes each issue individually from public web sources, at the depth you asked for. Two subscribers never receive the same newsletter.

Because biotech news unfolds in trial phases rather than hourly cycles, most readers choose weekly or every-two-days delivery, though daily is available. The steering mechanism is a reply: 'more on neurodegeneration, less on funding rounds' redirects your next issue. Briefed is 100% free - no paid tier, no ads, no credit card - with 30-second setup, double opt-in, and one-click unsubscribe. It informs; it is not medical or investment advice.

Sample issue

An example of what a Biotech issue could look like. Yours is written fresh for you, every time.

Gene editing moves from platform promise to approved therapies

With the first CRISPR-based treatments on the market, attention shifts to manufacturing, pricing, and which indications come next.

AI-designed molecules reach the clinic

Computationally discovered candidates are entering human trials in growing numbers - the real test of whether AI compresses drug development timelines.

The obesity drug boom reshapes pharma pipelines

Metabolic disease has become the industry's center of gravity, pulling investment toward next-generation candidates and combination approaches.

Biomanufacturing capacity becomes a strategic bottleneck

As advanced therapies scale, the constraint is shifting from discovery to production - and to the geopolitics of where it happens.

Questions about Biotech

Do I need a science background to read it?

No - tell Briefed your level and it writes accordingly, from accessible explanation to literature-adjacent depth.

Can it follow specific disease areas or modalities?

Yes. Name them - oncology, neurodegeneration, gene therapy - and your issues center on those areas.

Is this investment advice for biotech stocks?

No. It is a personalized news and research brief from public sources, not investment guidance.

How much does it cost?

Nothing. Briefed is free with no ads or paid tier - double opt-in signup, one-click unsubscribe.

Related newsletters

Prefer to build your own Biotech digest? We publish complete DIY guides - ChatGPT API, n8n, Zapier, pure Python - with real code and honest costs.